Filter By:

Drug delivery technique makes cancer immunotherapy more effective

Researchers in the Institute for Molecular Engineering at the University of Chicago (IME) have developed a new way to target immunotherapies and deliver them directly to tumors.

New checkpoint inhibitor shows promise in clinical trial for non-Hodgkin’s lymphoma
Building on the promise of immunotherapy for melanoma